Kairos Pharma, LTD. — Director's Dealing 2025

Apr 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2025-01-01

Reporting Person: Bhowmick Neil (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-01	COMMON STOCK	A	14000	$0.00	Acquired	1139983	Direct

Footnotes

F1: Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof.

F2: Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting.